OakChart

Yarrow Bioscience Inc

YARWHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

18.05+2.57 (16.60%)
2026-11-12 03:34 CET
Market cap
170.35 USD m
Revenue, TTM
0.48 USD m
Net income, TTM
-18.71 USD m
Free cash flow, TTM
-16.93 USD m
EPS diluted, TTM
-23.46
P/E
-
Compare

Price

YARW against its 20, 50 and 200-day averages
2050200miss
20.0030.0040.00681K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26YARWclose 18.0520-day 18.3450-day 22.30200-day 21.7818.0552w high

59.2% under the 52-week high of 44.28 on 7 Aug 2026. 52-week low 9.65 on 21 Nov 2025. Last 15 sessions, 66.7% high to low

Volume 1.40× normal · the line is the 50-bar volume average

Profile

YARW
52-week range, 24% of the way up
9.6544.28

Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The company is developing YB-101, a potentially first-of-its-kind antibody therapy aimed at treating Graves disease (GD) and thyroid eye disease (TED). Yarrow Bioscience was founded in October 2025 and is headquartered in New Haven, CT.

Employees10
IPOJan 25, 2018
Beta2.08
ATR, 14d2.35
Rel volume1.40
Short float1.69%
Insider own10.87%
Inst own23.49%

Snapshot

6 groups

Valuation

Index-
Market Cap170.36M
Enterprise Value147.43M
Income-18.71M
Sales0.48M
Book/sh33.01
Cash/sh2.43
Dividend Est.-
Dividend TTM-
Dividend Ex-DateJul 24, 2026
Dividend Gr. 3/5Y- -
Payout-
Employees10
IPOJan 25, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S354.91
P/B0.55
P/C7.43
P/FCF-
EV/EBITDA-
EV/Sales307.14
Quick Ratio15.26
Current Ratio15.26
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-23.46
EPS next Y-3.39
EPS next Q-0.71
EPS this Y-
EPS next Y-
EPS next 5Y49.81%
EPS past 3/5Y-39.77% 66.27%
Sales past 3/5Y6.12% -51.39%
EPS Y/Y TTM48.11%
Sales Y/Y TTM1.26%
EPS Q/Q47.92%
Sales Q/Q40.58%
EarningsAug 13 BMO
EPS/Sales Surpr.-872.73% -

Ownership

Insider Own10.87%
Insider Trans0.00%
Inst Own23.49%
Inst Trans49.88%
ROA-55.24%
ROE-61.93%
ROIC-84.80%
Gross Margin95.23%
Oper. Margin-4134.65%
Profit Margin-3881.54%
SMA20-1.60%
SMA50-19.06%
SMA200-17.11%
Trades-

Technical

Shs Outstand9.44M
Shs Float8.41M
Short Float1.69%
Short Ratio1.06
Short Interest0.14M
52W High44.28 -59.23%
52W Low9.65 87.09%
Volatility19.89% 12.63%
ATR (14)2.35
RSI (14)46.08
Beta2.08
Rel Volume1.40
Avg Volume133.76K
Volume187,330

Performance

Perf Week21.06%
Perf Month-2.96%
Perf Quarter-57.75%
Perf Half Y-4.50%
Perf YTD10.30%
Perf Year78.63%
Perf 3Y-81.77%
Perf 5Y-97.35%
Perf 10Y-
Recom1.00
Target Price58.00
Prev Close15.48
Price18.05
Change %16.60%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Nov 06, 2026InitiatedGGuggenheimBuy$60+232.4%
Aug 03, 2026InitiatedBBTIG ResearchBuy$58+221.3%
Jul 31, 2025DowngradeBBTIG ResearchBuy → Neutral
Nov 18, 2024InitiatedBBTIG ResearchBuy$8-55.7%
Dec 06, 2021ResumedHH.C. WainwrightBuy$7-61.2%

Peers

Mkt cap
TickerCompanyMkt cap
SEPNSepterna Inc2.31B
IMVTImmunovant Inc7.67B
VRDNViridian Therapeutics Inc3.55B
ALMSAlumis Inc883.74M
ARGXArgen X SE ADR61.48B
ZBIOZenas Biopharma Inc1.95B
DNTHDianthus Therapeutics Inc5.03B
AMGNAMGEN Inc253.21B
CLDXCelldex Therapeutics Inc2.37B
SYRESpyre Therapeutics Inc10.14B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-2.140-0.220-2.1400.00-1
2026Q12026-05-07-32.500--4.1910.17--
2025Q32025-11-06-8.500-8.667-8.5050.170.133
2025Q22025-08-14-6.500-11.165-6.7300.070.153
2025Q12025-05-08-10.000-14.420-10.0900.200.052
2024Q42025-03-06-14.000-15.165-14.1120.080.153
2024Q32024-11-07-14.500-11.750-14.2730.120.112
2024Q22024-08-14-11.000-9.500-11.0310.200.112
2024Q12024-05-09-7.500-12.000-7.3290.100.101
2023Q42024-02-29-9.000-25.000-9.9650.080.151
2023Q32023-11-13-79.500-38.000-100.310.110.151
2023Q22023-08-14-140.5-129-153.60.140.052
2023Q12023-05-11-74.000-1,287-86.2060.100.002
2022Q42023-03-09-148.5-162-166.580.010.062
2022Q32022-11-10-144-141-145.60.170.053
2022Q22022-08-12-135-155.25-131.680.130.104

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-8,532-8,798-8,54710.6410.70
2019FY-11,124-10,750-10,0950.780.00
2020FY-2,673-2,752-7,09520.9921.43
2021FY-1,134-1,202-1,28214.7617.26
2022FY-296.5-426-11.3400.480.37
2023FY-122.5-383-138.480.420.50
2024FY-46.500-48.000-46.5000.500.53
2025FY--42.835-30.961-0.60
2026FY--40.335--0.35
2027FY--32.000--0.00
2028FY--32.000--13.60
2029FY--132.5--50.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-041000.000.000.00
2026Q3S2026-01-201000.200.200.20
2026Q3S2025-11-111100.200.200.20
2026Q3S2025-11-101100.200.200.20
2026Q3S2025-11-091100.200.200.20
2026Q3S2025-11-081100.200.200.20
2026Q3S2025-11-071100.200.200.20
2026Q3S2025-11-061100.200.200.20
2026Q3S2025-11-051000.100.100.10
2026Q3S2025-11-041000.100.100.10
2026Q3S2025-11-031000.100.100.10
2026Q3S2025-11-021000.100.100.10
2026Q3S2025-11-011000.100.100.10
2026Q3S2025-10-311000.100.100.10

Estimate history

EPS, annual-4555.368-8546.976-10095.48-7095.168-1282.437-11.34-138.48-46.766-30.961-23.4575
Period201720182019202020212022202320242025TTM
EPS, quarterly-11.031-14.273-14.112-10.09-6.73-8.505-7.258-4.191-3.505
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual4.58210.640.44320.9930.9310.4770.4240.5010.570.48
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1980.1210.0840.2020.0690.1690.130.0860.097
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0060.0060.010.0480.063.230.2820.2970.6660.668
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.2910.2950.2970.3190.3950.6350.6660.6670.668
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.480.570.500.420.480.9320.990.4410.64
Cost of Goods Sold Incl. D&A0.020.020.00--3.351.390.35-
Gross Profit0.460.550.50--11.4119.600.09-
Selling, General and Administrative Excl. Other20.3930.3044.1329.6834.7039.73113.6895.9765.15
Research and Development9.8419.2430.9516.3118.3919.5443.5351.2052.99
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-19.93-29.75-43.64-29.26-34.30-38.91-94.08-95.87-54.53
Interest Expense0.000.000.000.000.005.614.390.920.00
Unusual Expense0.000.000.000.000.000.00158.470.00-
Net Income Before Taxes-18.87-26.73-39.80-27.87-33.93-44.66-255.83-95.35-51.45
Income Taxes0.000.000.000.000.01-0.45-0.26-0.180.00
Consolidated Net Income-18.87-26.74-39.81-27.87-33.95-44.21-255.57-95.18-51.45
Net Income From Continuing Operations-18.87-26.74-39.81-27.87-33.95-44.21-255.57-95.18-51.45
Net Income-18.71-26.48-39.83-28.45-36.13-73.33-255.57-95.18-51.45
EPS (Recurring)-21.81-30.96-46.77-138.48-11.34-1,282.43-4,015.50-10,095.49-8,546.99
EPS (Basic, Before Extraordinaries)-23.46-30.96-46.77-138.48-11.34-1,282.44-7,095.17-10,095.48-8,546.98
EPS (Diluted)-23.46-30.96-46.77-138.48-11.34-1,282.44-7,095.17-10,095.48-8,546.98
EBITDA-19.91-29.73-43.63-29.26-34.22-38.80-93.73-95.52-54.51
Non-Operating Income (Expense)1.063.023.831.390.36-0.141.111.443.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.711.822.612.613.396.3813.213.573.64
Price To Sales Ratio57.9143.53284.7856.4518.0356.389.76355.498.39
Gross Margin95.2395.9699.20--1,225.2493.3720.99-
Operating Margin-4,134.65-5,219.12-8,709.98-6,900.47-7,189.73-4,179.48-448.13-21,641.76-512.55
Net Margin-3,881.54-4,646.14-7,950.90-6,710.38-7,574.00-7,876.37-1,217.40-21,484.88-483.51
Shares Outstanding0.670.670.300.283.230.060.050.010.01
Market Capitalization170.35170.3528.034.344.9130.83154.0663.8854.01

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.100.090.130.170.070.200.080.12
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.010.00-
Gross Profit0.090.080.120.160.060.200.08-
Selling, General and Administrative Excl. Other3.193.905.347.967.619.3912.8513.21
Research and Development0.790.822.985.264.886.129.6810.25
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.10-3.82-5.22-7.79-7.54-9.20-12.77-13.09
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.90-3.58-4.96-7.43-5.75-8.60-12.01-12.16
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.90-3.58-4.96-7.43-5.75-8.60-12.01-12.16
Net Income From Continuing Operations-2.90-3.58-4.96-7.43-5.75-8.60-12.01-12.16
Net Income-3.01-3.58-4.84-7.28-5.75-8.61-12.02-12.16
EPS (Recurring)-3.50-4.19-7.26-8.50-6.73-10.09-14.11-14.27
EPS (Basic, Before Extraordinaries)-3.50-4.19-7.26-8.50-6.73-10.09-14.11-14.27
EPS (Diluted)-3.50-4.19-7.26-8.50-6.73-10.09-14.11-14.27
EBITDA-3.10-3.81-5.21-7.79-7.54-9.19-12.77-13.09
Non-Operating Income (Expense)0.200.230.260.371.790.590.760.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.440.470.420.380.530.760.010.73
Price To Sales Ratio57.9156.2933.9127.36148.22111.44284.83162.40
Gross Margin93.8193.0296.1596.4591.3097.0395.24-
Operating Margin-3,197.94-4,437.21-4,014.62-4,610.65-10,930.43-4,552.97-15,202.38-10,819.01
Net Margin-3,100.00-4,168.60-3,720.77-4,307.69-8,340.58-4,262.87-14,311.90-10,047.11
Shares Outstanding0.670.670.670.640.400.320.300.30
Market Capitalization170.3511.2410.916.0118.4114.2328.0315.65

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments29.0161.5293.3130.9842.8559.4573.37136.2559.50
Short Term Receivables0.000.000.005.177.5815.820.140.000.79
Inventories0.000.000.000.000.007.401.360.000.00
Other Current Assets1.002.922.662.1312.754.591.563.253.57
Total Current Assets30.0164.4495.9638.2763.1987.2676.41139.5063.86
Net Property, Plant & Equipment0.090.210.210.000.352.144.580.150.03
Total Investments and Advances0.000.000.000.000.000.000.000.002.98
Intangible Assets--------0.00
Other Assets0.062.261.512.483.514.340.170.280.00
Total Assets30.1666.9197.6940.7667.0593.7481.16139.9366.87
Short Term Debt Incl. Current Port. of LT Debt0.000.100.120.000.350.761.090.000.00
Accounts Payable1.042.711.662.396.514.7819.353.292.46
Other Current Liabilities1.3512.015.766.9611.5515.928.886.255.36
Total Current Liabilities2.4014.827.549.3518.4121.4529.339.547.82
Long Term Debt0.000.000.100.000.0034.0333.380.000.00
Provision for Risks Charges0.000.000.000.000.000.310.420.000.00
Other Liabilities0.000.001.310.000.000.460.460.016.76
Total Liabilities2.4014.828.959.3518.4156.2563.589.5514.57
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.210.000.000.000.00109.33
Common Equity27.7752.0988.7331.2048.6437.4917.57130.38-57.03
Total Shareholders Equity27.7752.0988.7331.4148.6437.4917.57130.3852.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity27.7752.0988.7331.4148.6437.4917.57130.3852.29
Total Liabilities & Stockholders Equity30.1666.9197.6940.7667.0593.7481.16139.9366.87
Book Value Per Share41.66175.61314.699.66817.00781.011,734.3620,202.02-8,935.61
Tangible Book Value Per Share41.66175.61314.699.66817.00781.011,734.3620,202.02-8,935.61
Full-Time Employees1013101228106404332
Price to Book Ratio0.550.540.380.120.634.110.930.410.35
Return on Assets-55.09-48.37-40.26-83.28-54.99-295.61-86.10-49.75-53.39
Return on Equity-66.96-56.54-46.40-108.06-102.66-482.20-128.66-56.33-71.04
Return on Invested Capital-95.38-76.48-32.03-115.01-150.77-357.34-186.80-39.46-55.60
Quick Ratio12.534.3512.734.103.433.722.5614.628.17
Current Ratio12.534.3512.734.103.434.072.6114.628.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-18.71-26.48-39.83-28.45-23.21-73.33-255.57-95.18-51.45
Depreciation0.020.020.000.000.070.110.340.350.02
Other Funds (Non Cash)1.671.530.863.05-8.3412.08158.484.752.86
Funds from Operations-17.02-24.93-38.97-25.40-31.48-61.14-96.75-90.08-48.56
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.09-8.195.000.062.634.78-40.3316.68-4.17
Cash from Operating Activities-16.93-33.12-33.97-25.34-28.85-56.37-137.08-73.39-52.73
Capital Expenditures0.000.00-0.120.000.000.00-0.11-1.06-0.14
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.005.0015.670.0038.640.04-
Purchase or Sale of Investments17.8637.3723.48-62.350.001.0350.5842.89-33.74
Purchase of Investments-7.59-30.93-60.52-62.350.000.000.00-44.96-126.70
Sale Or Maturity of Investments25.4568.3084.00-0.001.0350.5887.8592.96
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities17.8637.3723.36-57.3515.671.0389.1141.87-33.88
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.000.000.0082.391.6576.2161.8114.05125.91
Repurchase of Common Pref Stock0.000.000.00-0.360.00-0.29-0.14-0.030.00
Sale of Common Pref Stock0.000.000.0082.751.6576.5061.9514.08125.91
Proceedsfrom Stock Options0.000.000.0082.821.6575.9861.6413.71125.42
Issuance or Reduction of Debt, Net0.000.000.000.00-0.35-36.430.0033.900.00
Change in Long Term Debt0.000.000.000.000.00-36.430.0033.900.00
Issuance of Long Term Debt0.000.000.000.000.000.000.0033.900.00
Reduction of Long Term Debt0.000.000.000.000.00-36.430.000.000.00
Net Financing Active Other Cash Flow-0.05-0.14-0.140.000.000.000.000.000.00
Other Financing Activities Uses-0.05-0.14-0.140.000.000.000.000.000.00
Cash from Financing Activities-0.05-0.14-0.1482.391.3039.7861.8147.95125.91
Exchange Rate Effect-----0.000.000.04-
Net Change in Cash0.884.10-10.75-0.30-11.88-15.5613.8316.4739.30
Free Cash Flow-16.93-33.12-34.09-25.34-28.85-56.37-137.19-74.45-52.87
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments22.9324.9329.0132.7039.6550.27
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.600.861.003.194.704.64
Total Current Assets23.5325.7930.0135.8944.3454.91
Net Property, Plant & Equipment0.080.080.090.100.130.17
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.00----
Other Assets0.000.000.060.150.241.34
Total Assets23.6025.8730.1636.1344.7256.42
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.030.06
Accounts Payable0.610.261.041.201.413.53
Other Current Liabilities0.930.971.352.854.408.69
Total Current Liabilities1.541.242.404.045.8412.29
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.541.242.404.045.8412.29
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity22.0624.6427.7732.0938.8844.13
Total Shareholders Equity22.0624.6427.7732.0938.8844.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity22.0624.6427.7732.0938.8844.13
Total Liabilities & Stockholders Equity23.6025.8730.1636.1344.7256.42
Book Value Per Share33.0136.9341.6650.5098.32138.26
Tangible Book Value Per Share33.0136.9341.6650.5098.32138.26
Full-Time Employees--10---
Price to Book Ratio0.550.460.390.190.470.32
Return on Assets-55.24-52.78-55.09-60.16-58.65-56.95
Return on Equity-61.93-63.16-66.96-70.67-67.73-66.15
Return on Invested Capital-13.63-14.55-17.42-22.69-14.80-19.51
Quick Ratio15.2620.8612.538.877.604.47
Current Ratio15.2620.8612.538.877.604.47

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-3.01-3.58-4.84-7.28-5.75-8.61
Depreciation0.010.010.010.010.010.01
Other Funds (Non Cash)0.430.460.440.340.320.44
Funds from Operations-2.57-3.12-4.39-6.94-5.43-8.17
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.58-0.960.63-0.16-5.37-3.29
Cash from Operating Activities-1.99-4.08-3.76-7.10-10.80-11.46
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.304.708.464.404.6719.83
Purchase of Investments0.000.00-0.79-6.80-9.57-13.77
Sale Or Maturity of Investments0.304.709.2511.2014.2533.60
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.304.708.464.404.6719.83
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.01-0.01-0.01-0.01-0.03-0.09
Other Financing Activities Uses-0.01-0.01-0.01-0.01-0.03-0.09
Cash from Financing Activities-0.01-0.01-0.01-0.01-0.03-0.09
Net Change in Cash-1.710.604.68-2.70-6.168.28
Free Cash Flow-1.99-4.08-3.76-7.10-10.80-11.46

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 501.00K 2025: 570.00K
United States2024: 501.00K 2025: 570.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.69%0.1M8.4M112.91K
2026-10-151.57%0.1M8.4M93.38K
2026-09-302.25%0.2M8.4M90.24K
2026-09-151.54%0.1M8.2M64.31K
2026-08-312.41%0.1M2.3M36.28K
2026-08-140.83%0.0M2.3M29.51K
2026-07-310.58%0.0M2.2M28.45K
2026-07-150.53%0.0M0.7M18.70K
2026-06-300.35%0.0M0.6M3.07K
2026-06-150.37%0.0M0.6M3.47K
2026-05-290.38%0.0M0.6M3.68K
2026-05-150.39%0.0M0.6M4.47K
2026-04-300.38%0.0M0.6M4.44K
2026-04-150.32%0.0M0.6M5.87K
2026-03-310.39%0.0M0.6M7.12K
2026-03-130.60%0.0M0.6M102.74K
2026-02-270.68%0.0M0.6M103.07K
2026-02-131.75%0.0M0.6M104.99K
2026-01-301.77%0.0M0.6M108.81K
2026-01-152.45%0.0M0.6M111.76K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-07SCHEDULE 13GSEC
2026-09-17SCHEDULE 13GSEC
2026-09-148-KCurrent report2026-09-10SEC
2026-09-11424B5SEC
2026-09-11424B5SEC
2026-09-108-KCurrent report2026-09-10SEC
2026-08-19EFFECTEffectiveness filing by commission orderSEC
2026-08-14SCHEDULE 13GSEC
2026-08-14POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-K/A2026-07-24SEC
2026-08-07SCHEDULE 13GSEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-05SCHEDULE 13DSEC
2026-08-04SCHEDULE 13GSEC
2026-08-03SCHEDULE 13GSEC
2026-07-30SCHEDULE 13GSEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-308-KCurrent report2026-07-29SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-27SEC
2026-07-293Initial statement of beneficial ownership of securities2026-07-27SEC
2026-07-29SCHEDULE 13D/ASEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Nantahala Capital Management, LLC11.98%
ADAR1 Capital Management, LLC8.84%
Lynx1 Capital Management LP4.88%
Shay Capital LLC4.36%
Deeter Investments LLP3.00%
T3 Companies, LLC2.83%
BRAIDWELL LP2.74%
KVP Capital Advisors, LP1.50%
CITADEL ADVISORS LLC1.40%
TWO SIGMA INVESTMENTS, LP1.31%

Funds

Fund% owned
Columbia Small Cap Growth Fund5.68%
Fidelity Extended Market Index Fund0.11%
Fidelity Series Total Market Index Fund0.03%
Fidelity Total Market Index Fund0.02%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. YARW. Cached 15 minutes.

Some panels did not load: insider.